Zelira Therapeutics Limited

Equities

ZLD

AU000000ZLD1

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 01:34:10 2024-04-19 am EDT			5-day change	1st Jan Change
0.71 ^AUD	-1.39%		+2.90%	-21.11%

Apr. 15	Zelira Therapeutics Receives AU$919,000 Funding Under Australian Government’s R&D Tax Incentive Scheme	MT
Feb. 22	Zelira Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Zelira Therapeutics : Consolidation/Split - ZLD

March 13, 2022 at 11:44 pm EDT

Notification of Consolidation/Split

Announcement Summary

For personal use only

Entity name

ZELIRA THERAPEUTICS LIMITED

Applicable security for the reorganisation

ZLD	ORDINARY FULLY PAID
ZLDAA	OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES
ZLDAF	PERFORMANCE RIGHTS
ZLDAL	OPTION EXPIRING 13-NOV-2023 EX $0.07
ZLDAG	OPTION EXPIRING 11-SEP-2023 EX 10C
ZLDAH	OPTION EXPIRING 11-SEP-2023 EX 15C
ZLDAI	OPTION EXPIRING 11-SEP-2023 EX 20C
ZLDAJ	OPTION EXPIRING 11-SEP-2023 EX 28C
ZLDAK	OPTION EXPIRING 11-SEP-2023 EX 30C
Announcement Type
New Announcement
Date of this announcement
14/3/2022
Reorganisation type
Security consolidation

Trading in the post consolidation or split +securities commences on a deferred settlement basis

14/4/2022

Record Date

19/4/2022

Issue Date

27/4/2022

Notification of Consolidation/Split

1 / 8

Notification of Consolidation/Split

Refer to below for full details of the announcement

For personal use only

Notification of Consolidation/Split

2 / 8

Notification of Consolidation/Split

Announcement Details

only
	Part 1 - Entity and announcement details
		1.1 Name of +Entity
		ZELIRA THERAPEUTICS LIMITED
		1.2 Registered Number Type		Registration Number
use	ABN
	27103782378
1.3 ASX issuer code


		ZLD
		1.4 The announcement is
personal	New announcement
1.5 Date of this announcement

		14/3/2022
		1.6 Securities affected by the consolidation or split
		ASX +Security Code	ASX +Security Description
		ZLD	ORDINARY FULLY PAID
		ZLDAA	OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES
For	ZLDAF	PERFORMANCE RIGHTS
ZLDAL	OPTION EXPIRING 13-NOV-2023 EX $0.07

		ZLDAG	OPTION EXPIRING 11-SEP-2023 EX 10C
		ZLDAH	OPTION EXPIRING 11-SEP-2023 EX 15C
		ZLDAI	OPTION EXPIRING 11-SEP-2023 EX 20C

Notification of Consolidation/Split

3 / 8

Notification of Consolidation/Split

ZLDAJ	OPTION EXPIRING 11-SEP-2023 EX 28C
ZLDAK	OPTION EXPIRING 11-SEP-2023 EX 30C

onlyPart 2 - Approvals

2.1 Are any of the below approvals required for the consolidation or split before business day 0 of the timetable? Security holder approval

Court approval

Lodgement of court order with +ASIC

ACCC approval

FIRB approval

Another approval/condition external to the entity required to be given/met before business day 0 of the timetable for the consolidation or split.

use	Yes
2.2	Approvals
Approval/Condition	Date for determination	Is the date estimated or	Approval
personal	+Security holder approval	12/4/2022		actual?	received/condition met?
	Actual


		Comments


	Part 3 - Consolidation or split timetable and details

		3.1	+Record date
		19/4/2022
		3.2	Date of +security holder meeting
		12/4/2022
For	3.2a Effective date of consolidation or split
12/4/2022

		3.3	Last day for trading in the pre consolidation or split +securities
		13/4/2022
		3.4	Trading in the post consolidation or split +securities commences on a deferred settlement basis.
		14/4/2022
		3.5	Record date
		19/4/2022

Notification of Consolidation/Split

4 / 8

Notification of Consolidation/Split

3.6 First day for entity to update its register and to send holding statements to +security holders reflecting the change in the number of +securities they hold.

20/4/2022

3.7 Last day for entity to update its register and send holding statements to +security holders reflecting the change in the number of +securities they hold and to notify ASX that this has occurred. (+Issue Date)

only	27/4/2022
3.8 Trading starts on a normal T+2 basis

		28/4/2022
		3.9 First settlement of trades conducted on a +deferred settlement basis and on a normal T+2 basis
use	2/5/2022

	Part 4 - Event type and details

		4.1 The event is
		+Security consolidation
		4.1a Consolidation ratio: the +securities will be consolidated on the basis that every
personal	175
5.1 +Securities on issue before and after the consolidation or split
		(pre-consolidation) +securities will be consolidated into
		1
		(post-consolidation) +security (/ies).
		4.2 Scrip fraction rounding
		Fractions rounded up to the next whole number
	Part 5 - +Securities on issue before and after consolidation or split

For	ASX +Security Code	ASX +Security Description

		ZLD	ORDINARY FULLY PAID
		Quoted/unquoted	Number on issue pre	Number on issue post	Estimate/Actual
		Quoted	consolidation or split	consolidation or split	Estimated

				1,675,101,964	9,572,011
		ASX +Security Code	ASX +Security Description
		ZLDAA	OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES
		Quoted/unquoted			Estimate/Actual
		Unquoted			Estimated

	Notification of Consolidation/Split		5 / 8

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

Original Link
Original Document
Permalink

Disclaimer

Zelda Therapeutics Ltd. published this content on 14 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 March 2022 03:43:05 UTC.

Latest news about Zelira Therapeutics Limited

Zelira Therapeutics Receives AU$919,000 Funding Under Australian Government’s R&D Tax Incentive Scheme	Apr. 14	MT
Zelira Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 22	CI
Zelira Therapeutics Secures Grant Funding for Cannabinoid Product	Jan. 07	MT
Transcript : Zelira Therapeutics Limited - Shareholder/Analyst Call	Nov. 14
Zelira Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Zelira Therapeutics Limited Announces Board Changes	23-05-31	CI
Transcript : Zelira Therapeutics Limited - Special Call	23-05-30
Zelira Therapeutics Bags Nearly AU$5 Million More Investment for HOPE SPV; Shares Rise 4%	23-05-21	MT
Zelira Therapeutics Limited announced that it expects to receive $22 million in funding	23-05-21	CI
Zelira Therapeutics Raises AU$1.8 Million Via Placement	23-03-15	MT
Zelira Therapeutics Halts Securities Trading Pending Capital Raising Announcement	23-03-13	MT
Zelira Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-27	CI
Transcript : Zelira Therapeutics Limited - Special Call	23-02-21
Zelira Therapeutics Limited Promotes Greg Blake from VP - Global Head of Commercial and Partnering to Executive Director	23-02-19	CI
Zelira Therapeutics Secures Nearly $9 Million Funding for US Clinical Trials of HOPE	23-02-15	MT
Zelira Therapeutics Secures R&D Tax Rebate	23-01-30	MT
Zelira Therapeutics Completes Drug Trial Patient Enrolment	22-11-21	MT
Transcript : Zelira Therapeutics Limited - Shareholder/Analyst Call	22-11-16
Zelira Therapeutics Launches ZYRAYDI™ B2b Technology to Create Pharma-Grade Cannabis Capsules & Tablets for Global Markets	22-09-20	CI
Zelira Therapeutics Enrolls Two-Thirds of Patients for Diabetic Nerve Pain Medication	22-09-14	MT
Zelira Therapeutics Limited Completes Two-Thirds of Enrolment for Diabetic Nerve Pain Drug Trial	22-09-14	CI
Zelira Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-31	CI
Zelira Therapeutics Limited Auditor Raises 'Going Concern' Doubt	22-08-30	CI
Zelira's Zenivol™, the First Clinically Validated Cannabinoid Medication for Insomnia, Achieves Regulatory Approval in Germany	22-07-21	CI
Zelira Therapeutics Secures German Regulatory Approval for Insomnia Drug; Shares Rally 13%	22-07-13	MT

Chart Zelira Therapeutics Limited

Duration

Period

More charts

Company Profile

Zelira Therapeutics Limited is an Australia-based biopharmaceutical company. The Company is engaged in the research, development and commercialization of clinically validated cannabinoid-based medicines. It owns a portfolio of products and a pipeline of candidates undergoing clinical development positioned to enter global markets. It is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription [Rx] business for the treatment of a variety of medical conditions, including insomnia, autism and chronic non-cancer pain, as well as offering over the counter [OTC] products. It has two medications: HOPE and ZENIVOL. ZENIVOL is a cannabinoid-based medicine for the treatment of chronic insomnia. The Company in partnership with SprinJeneCBD, introduced a full line of oral care products, including SprinJeneCBD toothpaste product, which is a hemp-derived, oral care products containing cannabinoids, blackseed oil and zinc utilizing patented technology.

Sector

Biotechnology & Medical Research

Calendar

2024-08-28 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ZELIRA THERAPEUTICS LIMITED	-21.11%	5.26M
VERTEX PHARMACEUTICALS INCORPORATED	-3.10%	102B
REGENERON PHARMACEUTICALS, INC.	+2.11%	96.07B
ARGENX SE	-1.80%	21.66B
BIONTECH SE	-17.75%	20.77B
GENMAB A/S	-6.91%	18.53B
WUXI APPTEC CO., LTD.	-42.00%	16.91B
BEIGENE, LTD.	-28.19%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.18%	13.33B
SAREPTA THERAPEUTICS, INC.	+19.90%	10.94B

Bio Therapeutic Drugs